02/01/12 - Sophia-Antipolis, France

MEDIAN signe un contrat majeur avec Sanofi

MEDIAN Technologies signe un contrat majeur avec le laboratoire SANOFI pour l’interprétation et la gestion des images dans une nouvelle étude de phase II sur le cancer du poumon à petites cellules.

 
More info >  (413.2 Kb, PDF File)

02/01/12 - Sophia-Antipolis, France

MEDIAN has signed a landmark contract with Sanofi

MEDIAN Technologies has signed a landmark contract with the top pharmaceutical company SANOFI for medical image interpretation and management in a new phase II study on small cells lung cancer.

 
More info >  (408.8 Kb, PDF File)
 
/ Home
/ News

Press Releases

< Back to News List
MEDIAN Technologies Welcomes Oran Muduroglu to its Board of Directors
02/03/09 - Sophia Antipolis, France

MEDIAN Technologies, a leading provider of advanced clinical applications for oncology imaging, today announced it has recently appointed Oran Muduroglu to its Board of Directors. Mr. Muduroglu will hold the position of Strategic Advisor for the company. With this addition, MEDIAN board now consists of seven members.

In prior years, Mr. Muduroglu was the CEO of Philips Medical Systems' Healthcare Informatics Group and co-founder and CEO of Stentor, a leading provider of Enterprise enabled PACS solutions and disruptive service based business models. “Coming from the PACS industry, I was very impressed by MEDIAN’s integration capabilities that allow high-end clinical applications to be delivered at an enterprise level,” said Oran Muduroglu. “The success of last RSNA showed that the company has perfectly understood the critical needs of both the clinicians working with oncology patients, and the PACS providers.”

Fredrik Brag, CEO of MEDIAN Technologies explains: "We welcome Oran who will play an essential role in helping the company move forward in its strategic positioning in the US market. His extensive experience in the healthcare sector is a very valuable complement to the Board's range of talents."

About MEDIAN Technologies

MEDIAN Technologies develops and sells clinical applications for quantitative assessment of response to therapy in oncology imaging. The company’s product line, MEDIAN LMS – Lesion Management Solutions – is a comprehensive portfolio of software applications for the management of cancerous or suspicious lesions diagnosed in CT scans. LMS applications feature LMS-Lung, LMS-Liver and LMS-Colon.